 |
 |
To my mind, there is but one logic. PD is due to a lack of a neurotransmitter, namely l-dopamine. The simplest way to remedy the situation is to replenish that which is missing. Erzats drugs, also called 'agonists', try to replicate the activity of l-dopa, and are effective to some degree, but only the real thing can act like the real thing. The side effects of l-dopa are likely due to the inefficient biological paths of the excess medication which can be difficult to titrate especially for neurologists poorly familiar with PD. I do keep my ears and eyes open to advances in the field, and I am particularly hopeful that research with stem cells will bear fruits soon. Michel 'Carpe Diem' "J. R. Bruman" wrote: > As may be seen from the numerous current contributions on this > topic, there's plenty of evidence, but a final sweeping verdict is not > > in. It's true, Sinemet has its drawbacks, but so do the various > agonists, and perhaps in most cases the choice to go one way or the > other (just like many others of life's choices) isn't so critical. > Cheers,